CCTV+:Chinese and European Media Carry Out Multilateral Cooperation to Achieve Win-Win Results
10.12.2020 12:30:00 EET | Business Wire | Press release
A statement on strengthening media cooperation issued by China Media Group (CMG) and its European media partners, calling on the Chinese and European media to fulfill their responsibilities as public information disseminators and jointly help the international community to gather a strong force to overcome the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005312/en/
CMG and its European media partners issued the statement. /CCTV+ (Photo: Business Wire)
CMG and its European media partners issued the statement. /CCTV+
The statement was made during the “2020 European Media Partners Cooperation Online Forum” on December 10, hosted by CMG with the theme of “Mutual Trust Dialogue for Win-Win Cooperation”.
Twenty-eight delegates from 25 organizations in 16 European countries and China had in-depth discussions on how to strengthen coordination, deepen ties, unite to fight the pandemic, and bring greater confidence to the world through in-depth exchanges.
CMG’s President and Editor-in-Chief, Shen Haixiong put forward three proposals on the current media situation. He said, “First, we should deepen cooperation in reporting COVID-19 responses; Second, we should promote the exchange of personnel between the media organizations; Third, we should strengthen the construction of our cooperation mechanism.”
In his speech, he pointed out, China and Europe share a broad consensus and common interests in supporting and practicing multilateralism, strengthening the global response to COVID-19, and jointly promoting global economic recovery and addressing the issue of climate change. We share far more consensus than divergences. Chinese and European media partners will also move towards a new stage of closer, deeper, and more pragmatic dialogue, exchange and cooperation.
Michael Friedenberg, the President of Reuters, said, “We must recognize the power of partnerships in this new media ecosystem. This can take the form of collaborative journalism, industry coalitions, new commercial business opportunities, content-sharing or shared platforms.”
He also mentioned CMG and CCTV+ are important partners and our partnership continues to be a priority.
“Without a clear two-way information communication, there will never be full trust and in-depth cooperation. Therefore, in a friendly relation between different countries and peoples, the media plays a vital role,” said Paolo Panerai, the Editor-in-Chief & CEO of Class Editori S.p.A.’s.
“As global interdependence grows, I believe that media companies cannot work in silos anymore,” Michael Peters, CEO and President of Executive Board of Euronews emphasized. He believes that Euronews and CMG will continue to deepen our collaboration in fostering a better understanding between our cultures.
A launch ceremony of China Business Video (CBV) was also held between CCTV+ and Reuters. It provides Reuters’ customers with financial news content from China, which will be distributed straight by CMG to improve media cooperation between China and other media and to strengthen information exchanges.
At the forum, Teng Yunping, President of CCTV Video News Agency (CCTV+), and Adrian Wells, Managing Director of European News Exchange (ENEX) signed a Strategic Memorandum of Understanding, which signals the official launch of the “European Media Partners (EMP)”. In the future, the two sides will strengthen cooperation on news materials, news reports, overseas reporters, news products, and media forums.
At the same time, the program, BizToday, was released to provide “European Media Partners” with tailored Chinese and European financial news jointly created by CMG, CCTV+ and ENEX.
During the forum, representatives from China and Europe joined an online panel discussion with the theme “Multilateral Cooperation and Mutual Trust, Common Challenges and Win-Win Future” to discuss how the Chinese and European media promote mutual trust between people from both sides and carry out multilateral cooperation to achieve win-win results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005312/en/
Contact information
CCTV+(China）
YU Xiao
Email: yuxiao@cctvplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom